Gastrointestinal Tumor – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Gastrointestinal Tumor – Drugs In Development, 2023’, provides an overview of the Gastrointestinal Tumor pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Gastrointestinal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastrointestinal Tumor and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Tumor
- The report reviews pipeline therapeutics for Gastrointestinal Tumor by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Gastrointestinal Tumor therapeutics and enlists all their major and minor projects
- The report assesses Gastrointestinal Tumor therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Gastrointestinal Tumor
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Tumor
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Tumor pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Akeso IncAlphamab Oncology
Arbele Ltd
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
BeiGene Ltd
Beijing Konruns Pharmaceutical Co Ltd
Bexion Pharmaceuticals Inc
Bold Therapeutics Inc
Bristar Immunotech Biotechnology Co Ltd
Centrymed Pharmaceutical Inc
Coherent Biopharma
Curegenix Inc
Diverse Biotech Inc
Eisai Co Ltd
Elicio Therapeutics Inc
Elpiscience Biopharma Ltd
Ex Seven Research LLC
FutureGen Biopharm Technology Co Ltd
Gansu Provincial People's Hospital
Genor BioPharma Co Ltd
GV20 Therapeutics LLC
Hutchison MediPharma Ltd
Imugene Ltd
Incyte Corp
Innovent Biologics Inc
Inspirna Inc
Kexing Biopharm Co Ltd
LaNova Medicines Ltd
LaunXP Biomedical Co Ltd
Merck & Co Inc
Minneamrita Therapeutics LLC
NB Health Laboratory Co Ltd
Peking University
Pfizer Inc
Portage Biotech Inc
Processa Pharmaceuticals Inc
RedHill Biopharma Ltd
Shandong Boan Biotechnology Co Ltd
Shanghai Gencells Therapeutics Co Ltd
Shanghai Grit Biotechnology Inc
Shanghai Yuyao Biotechnology Ltd
Shorla Oncology
Stemline Therapeutics Inc
Suzhou Immunofoco Biotechnology Co Ltd
Systimmune Inc
T-Knife GmbH
Tachyon Therapeutics Inc
Taiho Oncology Inc
Teclison Ltd
TOT Biopharm Co Ltd
TransThera Sciences (Nanjing) Inc
Wuhan Binhui Biopharmaceutical Co Ltd
Xiangxue Pharmaceutical Co Ltd
XtalPi Inc
Xuzhou Medical University
Zhejiang Teruisi Pharmaceutical Co Ltd